An early clinical study on VGN-R08b injection, a gene therapy product independently developed by Vitalgen, for the treatment of type II Gaucher disease (GD2) was initiated successfully
The first clinical study on the gene therapy product named VGN-R08b injection independently developed by Shanghai Vitalgen Biomedical Co., Ltd. (hereinafter referred to as "Vitalgen"), titled an exploratory clinical study to evaluate the tolerability and safety of VGN-R08b by intracerebroventricular injection in patients with type II Gaucher disease, was successfully initiated in Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine on March 1, 2023.